QUOTE AND NEWS
Market Intelligence Center  Mar 26  Comment 
After Wednesday’s trading in United Therapeutics (UTHR) MarketIntelligenceCenter.com's option trade-picking algorithms uncovered a trade that offers a 5.74% or 41.87% (for comparison purposes only), while providing 7.03% downside protection. The...
Market Intelligence Center  Mar 11  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center  are highlighting two trades on United Therapeutics (UTHR) today after it closed at $163.84 on Tuesday. For more conservative...
FierceBiotech  Mar 10  Comment 
The FDA has approved United Therapeutics' Unituxin (dinutuximab) to treat pediatric patients with high-risk cases of neuroblastoma. And the regulatory win comes with a priority review vouch that may well be worth tens of millions of dollars.
Market Intelligence Center  Mar 10  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center are highlighting two trades on United Therapeutics (UTHR) today after it closed at $160.44 on Monday. For more conservative...
TheStreet.com  Feb 27  Comment 
NEW YORK (The Deal) -- United Therapeutics is a rare example of a biotech startup that managed to thread the needle. The company was founded in 1996 by CEO Martine Rothblatt, who was already a wildly successful entrepreneur, co-founding Sirius...
Market Intelligence Center  Feb 25  Comment 
United Therapeutics (UTHR) was selected by MarketIntelligenceCenter.com’s trade-picking algorithms today after trading between $148.04 and $157.37 on Tuesday before closing at $155.16. A diagonal spread using a long position in the Jan. '16...
Market Intelligence Center  Feb 24  Comment 
United Therapeutics (UTHR) presents a trading opportunity that offers a 6.42% return in just 80 days. A covered call on United Therapeutics at the $150.00 level expiring on May. '15 offers an assigned return rate of 6.42% or 29.29% annualized....
Market Intelligence Center  Feb 12  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on United Therapeutics (UTHR) could yield about 7.79% (30.91% annualized, for comparison purposes only) in 92 days. Pair a long position in the stock with the May. '15...
FierceBiotech  Feb 11  Comment 
SteadyMed Therapeutics is heading to Nasdaq in search of $55 million (€49 million) to finance its assault on United Therapeutics' slice of the pulmonary arterial hypertension (PAH) market. The goal is to win market share by offering patients a...





You may also be interested in articles related to United Therapeutics (UTHR):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki